SOFINNOVA-PARTNERS
21.12.2023 18:07:32 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Andrew M. Weiss, an experienced leader in the medical devices industry whose ties to Sofinnova stretch back 20 years, as Venture Partner.
Mr. Weiss, who is based in San Francisco, will investigate global medical device investment opportunities across the Sofinnova Partners platform of strategies. He is currently an independent member on the boards of May Health and SafeHeal, two Sofinnova portfolio companies.
In 2013, Mr. Weiss was brought in as CEO to lead ReCor Medical, a company founded in 2009 by Mano Iyer, then an entrepreneur in residence at Sofinnova and now a partner in the Sofinnova medtech acceleration team. Mr. Weiss led ReCor, a pioneer in the use of ultrasound renal denervation to treat hypertension, as it scaled up to 175 employees, went through its clinical trials and was purchased by Otsuka Medical Devices in 2018. He also led preparations for ReCor’s US FDA PMA Approval, achieved in November of this year. Sofinnova Partners was the sole VC investor in ReCor at the time of the sale. Mr. Weiss retired from ReCor/Otsuka Medical Devices in April of 2023.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “It's fantastic to have Andy back working with Sofinnova Partners. He is an outstanding leader with impeccable credentials in the medical devices sector. His performance at ReCor, a pioneering company, is legendary."
Mr. Weiss said: “I share Sofinnova’s passion for finding, nurturing and bringing new medical device therapies to patients. Having worked both informally and as a portfolio company CEO with Sofinnova for the past 20 years, I know that they have the best team, and are the gold-standard medical device venture group on a global basis. I am honored to become part of this team.”
Before he took the reins at ReCor, Mr. Weiss held leadership roles including President & CEO of Vital Images (acquired by Toshiba), VP & General Manager of the Medtronic Surgical Navigation Systems and Neurological Businesses, and President & CEO of CoAxia, which was sold to Zoll Medical.
Mr. Weiss is a graduate of the Massachusetts Institute of Technology with a degree in mechanical engineering and has an MBA from the Columbia University Graduate School of Business.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231221098742/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arini Announces Final Close of Inaugural Direct Lending Fund, Targeting Over $4 Billion of Deployment21.10.2026 09:00:00 CEST | Press release
Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related vehicles are targeting deployment of over $4 billion, including anticipated leverage, making it among the largest debut European direct lending funds ever raised. Arini has built a sizeable initial portfolio throughout the fundraise, focusing on senior secured loans to borrowers demonstrating recurring and underwritable cash flow profiles and operating in industries with limited risk of disruption. Total deployment for the strategy is now approaching $2 billion across a range of sectors and geographies, alongside founder-led, family-owned and sponsor-backed businesses. This scale of deployment, in conjunction with Arini’s highly selective underwriting standards, demonstrates the depth of the European middle market opportunity set. Unlike in the US, banks in Europe have a dominant market share in corpor
LemFi Launches Its Biggest Product Expansion Yet Alongside a New Global Brand, ‘Ambition has no passport’21.10.2026 09:00:00 CEST | Press release
LemFi launches the biggest product expansion in its history, adding UK savings, credit, and data eSIM in 100+ destinations A rebuilt app brings transfers, savings, credit and connectivity together in one platform for people building financial lives across borders New global brand, “Ambition has no passport”, reflects LemFi’s evolution from remittances into a broader financial platform serving more than two million customers LemFi, the financial platform for people building lives across borders, today announced the launch of its new global brand platform, “Ambition has no passport”, alongside a completely rebuilt app, launching the largest product expansion in its history. More than two million customers use LemFi to move money to more than 30 countries, with over $2 billion in monthly transaction volume, and the company plans to add more countries next year. The expanded platform now includes savings and credit in the UK, eSIMs in more than 100 destinations, alongside LemFi’s existing
Skechers Wins Major Victory Against Kizik in Patent Infringement Suit21.10.2026 09:00:00 CEST | Press release
Munich Court States that Kizik’s Patent Infringement Case Against Skechers is “Largely Unfounded” Skechers U.S.A., Inc. (“Skechers”), the third largest footwear company in the world and leader in hands-free footwear technology, announced today that it won a major legal and commercial victory in a patent infringement lawsuit filed by Fast IP, LLC (“Kizik”) against Skechers before the Unified Patent Court (“UPC”) in Munich. Skechers, the market leader in hands-free footwear, sells thousands of styles of hands-free shoes worldwide under its Slip-ins and Swift Fit trademarks. In 2025, Kizik sued Skechers at the UPC for alleged patent infringement involving four of its thousands of hands-free styles. Skechers won on three of the four styles, with the fourth being a minor and commercially insignificant style for Skechers. In its ruling, the Munich Court stated that Kizik’s infringement claims are “largely unfounded.” Skechers’ leading hands-free footwear position globally is the result of it
AI and Multichannel Communication Come to Italian Municipalities21.10.2026 09:00:00 CEST | Press release
ANCIcomunicare and Audiencerate join forces on a new platform for local authorities, built on Microsoft AI and Cloud, distributed by Postel, a Poste Italiane Group company, and available through MEPA ANCIcomunicare and Audiencerate are partnering to provide Italian municipalities and local authorities with a new platform dedicated to data management and multichannel communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019549522/en/ ANCIcomunicare and Audiencerate launch a partnership to bring Italian municipalities a platform that simplifies data management and digital communication with citizens across all channels. The solution enables municipalities to manage, through a single digital system, communication campaigns aimed at citizens and businesses across multiple channels, including WhatsApp, SMS and e-mail. The platform also integrates Artificial Intelligence and Microsoft Copilot capabilities, designed to s
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom